# US 2021/0198650 A1 · Fragmented grs polypeptide and variant thereof, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198650 A1
- Document ID: US20210198650A1
- Status: Published application
- Kind: A1
- Application number: 17/057,363
- Filed: 2019-05-15
- Published: 2021-07-01
- Earliest claimed: 2018-05-23
- Assignees: Nibec Co., Ltd.
- Applicants: Curebio. Co., Ltd.
- Inventors: Sunghoon KIM; Peter Charles GOUGHNOUR
- Web page: https://patentgrep.com/patent/US20210198650A1

## CPC

- C12N 9/93: {Ligases (6)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 35/00: Antineoplastic agents
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/575: for cancer
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C12Y 601/01014: Glycine-tRNA ligase (6.1.1.14)
- G01N 2333/9015: Ligases (6)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a fragmented GRS polypeptide and a variant thereof, and a use thereof and, more specifically, to: an isolated polypeptide consisting of 8 to 170 consecutive amino acids including amino acids 531 to 538 in the amino acid sequence represented by SEQ ID NO: 1 or a polypeptide consisting of a variant having a sequence homology of 80% or more with the polypeptide; a fusion protein and a complex comprising the polypeptide; a polynucleotide coding for the polypeptide; and a use thereof for the prevention and treatment of neoplastic diseases, the detection of cancer cells, imaging, and drug delivery.

## Claims

### Claim 1

A polypeptide consisting of:
an isolated polypeptide consisting of consecutive 8 to 170 amino acid residues, which contains amino acids at positions 531 to 538 of an amino acid sequence defined by SEQ ID NO: 1; or
a variant having a sequence homology of 80% or more to the isolated polypeptide.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the isolated polypeptide or the variant specifically targets a cancer cell.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 2 to 6.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein the variant comprises a sequence having a sequence homology of 80% or more to any one amino acid sequence selected from the group consisting of SEQ ID NOS: 2 to 6.

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein the variant comprises the amino acid sequence defined by SEQ ID NO: 7.

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein the isolated polypeptide consists of 8 to 160 consecutive amino acids containing amino acids at positions 531 to 538 of the amino acid sequence defined by SEQ ID NO: 1.

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein the isolated polypeptide consists of 8 to 100 consecutive amino acids containing amino acids at positions 531 to 538 of the amino acid sequence defined by SEQ ID NO: 1.

### Claim 8 (depends on 1)

The polypeptide of claim 1, wherein the isolated polypeptide consists of 8 to 50 consecutive amino acids containing amino acids at positions 531 to 538 of the amino acid sequence defined by SEQ ID NO: 1.

### Claim 9 (depends on 1)

The polypeptide of claim 1, wherein the isolated polypeptide consists of 8 to 20 consecutive amino acids containing amino acids at positions 531 to 538 of the amino acid sequence defined by SEQ ID NO: 1.

### Claim 10 (depends on 1)

The polypeptide of claim 1, wherein the isolated polypeptide consists of 8 to 10 consecutive amino acids containing amino acids at positions 531 to 538 of the amino acid sequence defined by SEQ ID NO: 1.

### Claim 11 (depends on 1)

The polypeptide of claim 1, wherein the isolated polypeptide or the variant is in a linear or cyclic form.

### Claim 12 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide is in a PEGylated form.

### Claim 13 (depends on 1)

A fusion protein, comprising the polypeptide of claim 1 and a heterologous fusion partner.

### Claim 14 (depends on 13)

The fusion protein of claim 13, wherein the heterologous fusion partner is an antibody or a fragment thereof.

### Claim 15 (depends on 14)

The fusion protein of claim 14, wherein the fragment is selected from the group consisting of Fc, a diabody, Fab, Fab′, F(ab)2, F(ab′)2, Fv, and scFv.

### Claim 16 (depends on 1)

A dimeric or multimeric complex, comprising at least one polypeptide of claim 1.

### Claim 17 (depends on 1)

A polynucleotide encoding the polynucleotide of claim 1.

### Claim 18 (depends on 17)

An expression vector comprising the polynucleotide of claim 17.

### Claim 19 (depends on 18)

A host cell comprising the expression vector of claim 18.

### Claim 20 (depends on 1)

A composition, comprising a physiologically acceptable carrier and at least one selected from the group consisting of:
(i) the polypeptide of claim 1,
(ii) a fusion protein comprising the polypeptide of (i) and heterologous fusion partner,
(iii) a dimeric or multimeric complex comprising at least one polypeptide of (i),
(iv) a polynucleotide encoding (i) to (iii),
(v) an expression vector comprising (iv), and
(vi) a host cell comprising (v).

### Claim 21 (depends on 1)

A composition, comprising the polypeptide of claim 1 as an active ingredient.

### Claim at position 22

22-23. (canceled)

### Claim 24 (depends on 1)

A screening method for identifying an anticancer agent, the method comprising the steps of:
(a) forming a reaction mixture containing (i) and (ii):
(i) an ingredient selected from the group consisting of the polypeptide of claim 1,
(ii) a test compound; and
(b) determining an increase in an anti-cancer activity by the ingredient in the presence of the test compound, wherein a change in the anti-cancer activity in the presence of the test compound is determined compared to the anti-cancer activity in the absence of the test compound, thereby identifying an active test compound.

### Claim 25

(canceled)

### Claim 26 (depends on 21)

The composition of claim 21, wherein the polypeptide is labeled with at least one selected from the group consisting of a chromogenic enzyme, a radionuclide, a chromophore, a luminescent substance, a fluorescer, a super paramagnetic particle, or an ultrasuper paramagnetic particle.

### Claim 27 (depends on 1)

A method for detecting cancer cells, the method comprising the steps of:
(a) mixing the polypeptides of claim 1 with a biological sample;
(b) removing the polypeptides that remain unbound or are non-specifically bound; and
(c) determining whether and where the polypeptides are bound.

### Claim at position 27

28-31. (canceled)

### Claim 32 (depends on 1)

A composition comprising the polypeptide of claim 1 and an anticancer agent bound thereto as active ingredients.

### Claim 33 (depends on 17)

The polynucleotide of claim 17, comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 8 to 11.

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A method for prevention and treatment of a neoplastic disease, the method comprising a step of administering to a subject in need thereof an effective amount of a composition comprising the polypeptide of claim 1 as an active ingredient.

### Claim 36 (depends on 35)

The method of claim 35, wherein the neoplastic disease is selected from the group consisting of colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma, ovarian cancer, leukemia, myelodysplastic syndrome, polycythemia vera, lymphoma), cervical cancer, multiple myeloma, renal cell carcinoma, solid tumor, and angiogenesis-related diseases.

### Claim 37 (depends on 36)

The method of claim 36, wherein the angiogenesis-related disease is selected from the group consisting of age-related macular degeneration, diabetic blindness, endometriosis, ocular neovascularization, hemangioma, nevus flammeus, nevus simplex, diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, erythrosis, proliferative retinopathy, psoriasis, hemophilic arthropathy, capillary proliferation in atheromatous atherosclerotic plaques, keloid, wound granulation, angiostenosis, rheumatoid arthritis, osteoarthritis, autoimmune diseases, Crohn's disease, restenosis, atheromatous arteriosclerosis, cat scratch disease, ulcers, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy, glomerulopathy, and inflammation.

### Claim 38 (depends on 1)

A method for detecting or imaging cancer cells, the method comprising a step of administering to a subject in need thereof an effective amount of a composition comprising the polypeptide of claim 1 as an active ingredient.

### Claim 39 (depends on 38)

The method of claim 38, wherein the polypeptide is labeled with at least one selected from the group consisting of a chromogenic enzyme, a radionuclide, a chromophore, a luminescent substance, a fluorescer, a super paramagnetic particle, or an ultrasuper paramagnetic particle.

### Claim 40 (depends on 1)

A method for cancer cell-specific drug delivery, the method comprising a step of administering to a subject in need thereof an effective amount of a composition comprising the polypeptide of claim 1 as an active ingredient.

### Claim 41 (depends on 40)

The method of claim 40, wherein the drug is selected from the group consisting of paclitaxel, doxorubicin, vincristine, daunorubicin, vinblastine, actinomycin-D, docetaxel, etoposide, teniposide, bisantrene, homoharringtonine, Gleevec (STI-571), cisplain, 5-fluouracil, adriamycin, methotrexate, busulfan, chlorambucil, cyclophosphamide, melphalan, nitrogen mustard, nitrosourea, streptokinase, urokinase, alteplase, an angiotensin II inhibitor, an aldosterone receptor inhibitor, erythropoietin, an NMDA (N-methyl-d-aspartate) receptor inhibitor, lovastatin, rapamycin, celebrex, ticlopin, marimastat, and trocade.

### Claim 42 (depends on 1)

A method for prevention or treatment of cancer, the method comprising a step of administering to a subject in need thereof an effective amount of a composition comprising the polypeptide of claim 1 and an anticancer agent bound thereto.
